FDARA Section 504 eliminated the orphan exemption for pediatric studies for cancer drugs and instead empowers the FDA to require pediatric assessments of new therapies.
Not yet a member of Clinical Leader? Register today.
Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.
You might also want to: